Antony Johannes, Kellershohn Kerstin, Mohr-Andrä Marion, Kebig Anna, Prilla Stefanie, Muth Mathias, Heller Eberhard, Disingrini Teresa, Dallanoce Clelia, Bertoni Simona, Schrobang Jasmin, Tränkle Christian, Kostenis Evi, Christopoulos Arthur, Höltje Hans-Dieter, Barocelli Elisabetta, De Amici Marco, Holzgrabe Ulrike, Mohr Klaus
Pharmacology and Toxicology Section, Institute of Pharmacy, Rheinische Friedrich-Wilhelms-University, Bonn, Germany.
FASEB J. 2009 Feb;23(2):442-50. doi: 10.1096/fj.08-114751. Epub 2008 Oct 8.
Selective modulation of cell function by G protein-coupled receptor (GPCR) activation is highly desirable for basic research and therapy but difficult to achieve. We present a novel strategy toward this goal using muscarinic acetylcholine receptors as a model. The five subtypes bind their physiological transmitter in the highly conserved orthosteric site within the transmembrane domains of the receptors. Orthosteric muscarinic activators have no binding selectivity and poor signaling specificity. There is a less well conserved allosteric site at the extracellular entrance of the binding pocket. To gain subtype-selective receptor activation, we synthesized two hybrids fusing a highly potent oxotremorine-like orthosteric activator with M(2)-selective bis(ammonio)alkane-type allosteric fragments. Radioligand binding in wild-type and mutant receptors supplemented by receptor docking simulations proved M(2) selective and true allosteric/orthosteric binding. G protein activation measurements using orthosteric and allosteric blockers identified the orthosteric part of the hybrid to engender receptor activation. Hybrid-induced dynamic mass redistribution in CHO-hM(2) cells disclosed pathway-specific signaling. Selective receptor activation (M(2)>M(1)>M(3)) was verified in living tissue preparations. As allosteric sites are increasingly recognized on GPCRs, the dualsteric concept of GPCR targeting represents a new avenue toward potent agonists for selective receptor and signaling pathway activation.
通过G蛋白偶联受体(GPCR)激活来选择性调节细胞功能,对于基础研究和治疗而言是非常理想的,但却难以实现。我们以毒蕈碱型乙酰胆碱受体为模型,提出了一种实现这一目标的新策略。这五种亚型在受体跨膜结构域内高度保守的正构位点结合其生理递质。正构毒蕈碱激活剂没有结合选择性且信号特异性差。在结合口袋的细胞外入口处有一个保守性较差的变构位点。为了实现亚型选择性受体激活,我们合成了两种融合体,将一种高效的类震颤素正构激活剂与M(2)选择性双(铵)烷型变构片段融合。通过受体对接模拟补充的野生型和突变型受体中的放射性配体结合证明了M(2)选择性和真正的变构/正构结合。使用正构和变构阻滞剂进行的G蛋白激活测量确定了融合体的正构部分可引发受体激活。在CHO-hM(2)细胞中,融合体诱导的动态质量再分布揭示了途径特异性信号传导。在活体制备中验证了选择性受体激活(M(2)>M(1)>M(3))。由于变构位点在GPCR上越来越被认识到,GPCR靶向的双位点概念代表了一种获得强效激动剂以选择性激活受体和信号通路的新途径。